Erratum: Cell Therapy: A Safe and Efficacious Therapeutic Treatment for Alzheimer’s Disease in APP+PS1 Mice (PLoS ONE (2012) 7:12 (e49468) DOI: 10.1371/journal.pone.0049468);Cell Therapy: A Safe and Efficacious Therapeutic Treatment for Alzheimer's Disease in APP+PS1 Mice

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Nabar, Neel R ^a,b   Yuan, Fang ^c,d   Lin, Xiaoyang ^b   Wang, Li ^b   Bai, Ge ^e   Mayl, Jonathan ^b   Li, Yaqiong ^e   Zhou, Shu Feng ^a   Wang, Jinhuan ^f   Cai, Jianfeng ^e   Cao, Chuanhai ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f Huanhu Hospital of Tianjin   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; DENDRITIC CELL VACCINE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BRAIN HEMORRHAGE; CELL THERAPY; COGNITION; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; T LYMPHOCYTE; TRANSGENICS;

EID: 84870694592     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0303619     Document Type: Erratum

References (68)

1. Association As (2012) Alzheimer's disease facts and figures. Alzheimer's and Dementia: The Journal of the Alzheimer's Association. 131-168.
2. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. United States. 186-191.
3. Saxena U, (2011) Bioenergetics breakdown in Alzheimer's disease: targets for new therapies. Int J Physiol Pathophysiol Pharmacol 3: 133-139.
4. Götz J, Eckert A, Matamales M, Ittner L, Liu X (2011) Modes of Aβ toxicity in Alzheimer's disease. Cellular and Molecular Life Sciences: 1-17.
5. Ja H, Ga H, (1992)- Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185.
6. Octave JN, (1995) The amyloid peptide and its precursor in Alzheimer's disease. Rev Neurosci 6: 287-316.
7. Reitz C, Brayne C, Mayeux R, (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol. 7: 137-52.
8. Pillay NS, Kellaway LA, Kotwal GJ, (2004) Molecular mechanisms, emerging etiological insights and models to test potential therapeutic interventions in Alzheimer's disease. Curr Alzheimer Res 1: 295-306.
9. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177.
10. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, et al. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985.
11. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, et al. (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model. Nature 408: 979-982.
12. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, et al. (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. United States. 8850-8855.
13. Bard F, Cannon C, Barbour R, Burke RL, Games D, et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6: 916-919.
14. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, et al. (2005) Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology. United States. 94-101.
15. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, et al. (2009) Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 6: 144-151.
16. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46-54.
17. Merck (2007) A Study of V950 in People With Alzheimer Disease (V950-001). Bethesda (MD): National Library of Medicine (US): In: Clinicaltrials.gov [Internet].
18. Pfizer, JANSSEN Alzheimer Immunotherapy Research & Development L (2007) Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease. Bethesda (MD): National Library of Medicine (US): In: ClinicalTrials.gov [Internet]. Accessed 2011 Aug 30.
19. Novartus (2011) To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients. Bethesda (MD): National Library of Medicine (US): Clinicaltrials.gov [Internet].
20. Kutzler MA, Cao C, Bai Y, Dong H, Choe PY, et al. (2006) Mapping of immune responses following wild-type and mutant ABeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice. Vaccine 24: 4630-4639.
21. Maier M, Seabrook TJ, Lazo ND, Jiang L, Das P, et al. (2006) Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci. United States. 4717-4728.
22. Kim HD, Maxwell JA, Kong FK, Tang DC, Fukuchi K, (2005) Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: toward safer and effective vaccines against Alzheimer's disease. Biochem Biophys Res Commun 336: 84-92.
23. Satthaporn S, Eremin O, (2001) Dendritic cells (II): Role and therapeutic implications in cancer. J R Coll Surg Edinb 46: 159-167.
24. Loveland BE, Zhao A, White S, Gan H, Hamilton K, et al. (2006) Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res. United States. 869-877.
25. Cohen S, Haimovich J, Hollander N (2005) B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice. J Immunother. United States. 461-466.
26. Gajewski TF, Fallarino F, Ashikari A, Sherman M, (2001) Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 7: 895s-901s.
27. Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, et al. (2006) Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 106: 2309-2317.
28. Banchereau J, Steinman RM, (1998) Dendritic cells and the control of immunity. Nature 392: 245-252.
29. Cao C, Lin X, Zhang C, Wahi MM, Wefes I, et al. (2008) Mutant amyloid-beta-sensitized dendritic cells as Alzheimer's disease vaccine. J Neuroimmunol. Netherlands. 1-10.
30. Luo Z, Li Jialin, Nabar NR, Lin X, Bai G, et al. (2012) Efficacy of a therapeutic vaccine using mutated β-amyloid sensitized dendritic cells in Alzheimer's mice. J. Neuroimmune Pharmacology.
31. Parker KC, Bednarek MA, Coligan JE, (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152: 163-175.
32. Ethell DW, Shippy D, Cao C, Cracchiolo JR, Runfeldt M, et al. (2006) Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol Dis 23: 351-361.
33. Toellner KM, Luther SA, Sze DM, Choy RK, Taylor DR, et al. (1998) T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming. J Exp Med 187: 1193-1204.
34. Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, et al. (2001) Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 891: 42-53.
35. Postupna N, Rose SE, Bird TD, Gonzalez-Cuyar LF, Sonnen JA, et al. (2011) Novel Antibody Capture Assay for Paraffin-Embedded Tissue Detects Wide-Ranging Amyloid Beta and Paired Helical Filament-Tau Accumulation in Cognitively Normal Older Adults. Brain Pathol.
36. Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, et al. (2004) Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 55: 801-814.
37. Banchereau J, Steinman RM, (1998) Dendritic cells and the control of immunity. Nature 392: 245-252.
38. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373: 523-527.
39. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, et al. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102.
40. Bryan KJ, Lee H, Perry G, Smith MA, Casadesus G (2009) Transgenic Mouse Models of Alzheimer's Disease: Behavioral Testing and Considerations Methods of Behavior Analysis in Neuroscience; Buccafusco JJ, editor. Boca Raton FL: Taylor & Francis Group, LLC.
41. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4: 97-100.
42. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, et al. (1999) Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet 29: 177-185.
43. Morgan D, (2003) Learning and memory deficits in APP transgenic mouse models of amyloid deposition. Neurochem Res 28: 1029-1034.
44. Puolivali J, Wang J, Heikkinen T, Heikkila M, Tapiola T, et al. (2002) Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice. Neurobiol Dis 9: 339-347.
45. Leighty RE, Nilsson LN, Potter H, Costa DA, Low MA, et al. (2004) Use of multimetric statistical analysis to characterize and discriminate between the performance of four Alzheimer's transgenic mouse lines differing in Abeta deposition. Behav Brain Res. Netherlands. 107-121.
46. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842.
47. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. United States. 486-489.
48. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging. United States. 383-421.
49. Tuppo EE, Arias HR (2005) The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol. England. 289-305.
50. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, et al. (2002) Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 173: 183-195.
51. Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, et al. (2005)- Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 11: 328-334.
52. Pashenkov M, Huang YM, Kostulas V, Haglund M, Söderström M, et al. (2001) Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain 124: 480-492.
53. Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL, (2001) Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein. Proc Natl Acad Sci U S A 98: 10273-10278.
54. Tabira T (2010) Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J Exp Med. Japan. 95-106.
55. Sigurdsson EM, Wisniewski T, Frangione B (2002) A safer vaccine for Alzheimer's disease? Neurobiol Aging. United States. 1001-1008.
56. Smit WM, Rijnbeek M, van Bergen CA, de Paus RA, Vervenne HA, et al. (1997) Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Hum Immunol. United States. 216-223.
57. Gandy S, (2011) Perspective: prevention is better than cure. Nature 475: S15.
58. Bryan KJ, Lee H, Perry G, Smith MA, Casadesus G (2009) Transgenic Mouse Models of Alzheimer's Disease: Behavioral Testing and Considerations Methods of Behavior Analysis in Neuroscience; Buccafusco JJ, editor. Boca Raton FL: Taylor & Francis Group, LLC.
59. Dodart JC, Meziane H, Mathis C, Bales KR, Paul SM, et al. (1999) Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behav Neurosci 113: 982-990.
60. Katsel P, Tan W, Haroutunian V, (2009) Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals. PLoS One 4(10): e7642.
61. Morgan D, (2011) Immunotherapy for Alzheimer's disease. J Intern Med 269: 54-63.
62. Solomon B, Koppel R, Frankel D, Hanan-Aharon E, (1997) Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A 94: 4109-4112.
63. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, et al. (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. United States. 907-913.
64. Alcantar NA, Jimenez J, Morgan D, (2010) Direct observation of the kinetic mechanisms for Aß peptide aggregation: Towards elucidating Alzheimer plaque dissolution. Alzheimers Dement 6: S247.
65. Cao C, Arendash GW, Dickson A, Mamcarz MB, Lin X, et al. (2009) Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol Dis 34: 63-70.
66. Tsai KJ, Tsai YC, Shen CK (2007) G-CSF rescues the memory impairment of animal models of Alzheimer's disease. J Exp Med. United States. 1273-1280.
67. Fülöp TJ, Larbi A, Dupuis G, Pawelec G, (2003) Ageing, autoimmunity and arthritis: Perturbations of TCR signal transduction pathways with ageing- a biochemical paradigm for the ageing immune system. Arthritis Res Ther 5: 290-302.
68. Boyd TD, Bennett SP, Mori T, Governatori N, Runfeldt M, et al. (2010) GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and. J Alzheimers Dis 21: 507-518.